{"protocolSection": {"identificationModule": {"nctId": "NCT00529451", "orgStudyIdInfo": {"id": "CSPP100A2339"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg", "officialTitle": "An Eight Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing the Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg to Ramipril 5 mg in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-09"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-09-12", "studyFirstSubmitQcDate": "2007-09-13", "studyFirstPostDateStruct": {"date": "2007-09-14", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-16", "resultsFirstSubmitQcDate": "2011-02-28", "resultsFirstPostDateStruct": {"date": "2011-03-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-02-28", "lastUpdatePostDateStruct": {"date": "2011-03-25", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis"}, "leadSponsor": {"name": "Novartis", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is designed to investigate the efficacy, safety and tolerability of aliskiren 300 mg, 150 mg and 75 mg when compared to ramipril 5 mg in patients with essential hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, Aliskiren, Ramipril"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1613, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Aliskiren 300 mg", "type": "EXPERIMENTAL", "description": "Aliskiren 300 mg once daily", "interventionNames": ["Drug: Aliskiren"]}, {"label": "Aliskiren 150 mg", "type": "EXPERIMENTAL", "description": "Aliskiren 150 mg once daily", "interventionNames": ["Drug: Aliskiren"]}, {"label": "Aliskiren 75 mg", "type": "EXPERIMENTAL", "description": "Aliskiren 75 mg once daily", "interventionNames": ["Drug: Aliskiren"]}, {"label": "Ramipril 5 mg", "type": "ACTIVE_COMPARATOR", "description": "Ramipril 5 mg once daily", "interventionNames": ["Drug: Ramipril"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren", "description": "Aliskiren", "armGroupLabels": ["Aliskiren 150 mg", "Aliskiren 300 mg", "Aliskiren 75 mg"]}, {"type": "DRUG", "name": "Ramipril", "description": "comparator", "armGroupLabels": ["Ramipril 5 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "timeFrame": "Baseline and Week 8"}, {"measure": "Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "timeFrame": "Baseline and Week 8"}, {"measure": "Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "timeFrame": "Baseline and Week 8"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint", "description": "To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.", "timeFrame": "Baseline and Week 8"}, {"measure": "Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of < 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg", "description": "To evaluate the percentage of patients controlled to a target blood pressure of \\< 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.", "timeFrame": "Week 8"}, {"measure": "Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP < 90 mmHg or \u2265 10mmHg Decrease From Baseline in msDBP", "description": "To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP \\< 90 mmHg or \u2265 10mmHg decrease from baseline in msDBP.", "timeFrame": "Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have msDBP \u2265 90 mmHg and \\< 110 mmHg at the visit immediately prior to Visit 3\n* Patients must have msDBP \\>OR= 95 mmHg and \\< 110 mmHg at Visit 3\n* Patients must have an absolute difference of \\< or =10 mmHg in their mean sitting diastolic blood pressure (msDBP) from Visit 2 to Visit 3\n\nExclusion Criteria:\n\n* Severe hypertension (grade 3 WHO classification; msDBP \\>or= 110 mmHg and/or msSBP \\>or = 180 mmHg).\n* History or evidence of a secondary form of hypertension.\n* History of transient ischemic cerebral attack within 12 months of visit 1.\n* Current angina pectoris requiring pharmacological therapy (other than those patients on a stable dose of oral or topical nitrates)\n* Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c) \\> 8% at Visit 1.\n* Known or suspected contraindications to the study medications, including history of allergy to ramipril or other ACE Inhibitors.\n\nOther protocol-defined inclusion/exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis", "affiliation": "Novartis", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Novartis Investigative Sites", "city": "China", "country": "China"}, {"facility": "Novartis Investigative Sites", "city": "India", "country": "India"}, {"facility": "Novartis Investigative Sites", "city": "Thailand", "country": "Thailand"}]}, "referencesModule": {"references": [{"pmid": "33089502", "type": "DERIVED", "citation": "Wang GM, Li LJ, Tang WL, Wright JM. Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev. 2020 Oct 22;10(10):CD012569. doi: 10.1002/14651858.CD012569.pub2."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "FG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "FG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "FG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "331"}, {"groupId": "FG001", "numSubjects": "323"}, {"groupId": "FG002", "numSubjects": "332"}, {"groupId": "FG003", "numSubjects": "330"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "294"}, {"groupId": "FG001", "numSubjects": "275"}, {"groupId": "FG002", "numSubjects": "292"}, {"groupId": "FG003", "numSubjects": "299"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "37"}, {"groupId": "FG001", "numSubjects": "48"}, {"groupId": "FG002", "numSubjects": "40"}, {"groupId": "FG003", "numSubjects": "31"}]}], "dropWithdraws": [{"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "21"}, {"groupId": "FG002", "numSubjects": "13"}, {"groupId": "FG003", "numSubjects": "12"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "8"}]}, {"type": "Unsatisfactory therapeutic response", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "5"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "7"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "BG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "BG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "BG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "331"}, {"groupId": "BG001", "value": "323"}, {"groupId": "BG002", "value": "332"}, {"groupId": "BG003", "value": "330"}, {"groupId": "BG004", "value": "1316"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "53.8", "spread": "9.45"}, {"groupId": "BG001", "value": "53.3", "spread": "10.53"}, {"groupId": "BG002", "value": "52.7", "spread": "10.22"}, {"groupId": "BG003", "value": "52.9", "spread": "9.60"}, {"groupId": "BG004", "value": "53.2", "spread": "9.95"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "< 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "288"}, {"groupId": "BG001", "value": "273"}, {"groupId": "BG002", "value": "285"}, {"groupId": "BG003", "value": "296"}, {"groupId": "BG004", "value": "1142"}]}]}, {"title": "\u2265 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}, {"groupId": "BG001", "value": "50"}, {"groupId": "BG002", "value": "47"}, {"groupId": "BG003", "value": "34"}, {"groupId": "BG004", "value": "174"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "140"}, {"groupId": "BG002", "value": "144"}, {"groupId": "BG003", "value": "151"}, {"groupId": "BG004", "value": "585"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "181"}, {"groupId": "BG001", "value": "183"}, {"groupId": "BG002", "value": "188"}, {"groupId": "BG003", "value": "179"}, {"groupId": "BG004", "value": "731"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to 8 Week Endpoint", "description": "To evaluate the change in Mean Sitting Systolic Blood Pressure (msSBP) and Mean Sitting Diastolic blood Pressure (msDBP) from baseline to 8 week endpoint on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg in patients with essential hypertension.", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "OG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "OG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "318"}, {"groupId": "OG002", "value": "324"}, {"groupId": "OG003", "value": "323"}]}], "classes": [{"title": "msSBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.39", "spread": "0.66"}, {"groupId": "OG001", "value": "-12.16", "spread": "0.67"}, {"groupId": "OG002", "value": "-12.24", "spread": "0.66"}, {"groupId": "OG003", "value": "-11.46", "spread": "0.66"}]}]}, {"title": "msDBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.63", "spread": "0.44"}, {"groupId": "OG001", "value": "-10.04", "spread": "0.44"}, {"groupId": "OG002", "value": "-10.66", "spread": "0.44"}, {"groupId": "OG003", "value": "-9.19", "spread": "0.44"}]}]}]}, {"type": "SECONDARY", "title": "Evaluation of the Percentage of Patients Controlled to a Target Blood Pressure of < 140/90 mmHg on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg", "description": "To evaluate the percentage of patients controlled to a target blood pressure of \\< 140/90 mmHg on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg.", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "OG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "OG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "318"}, {"groupId": "OG002", "value": "324"}, {"groupId": "OG003", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "52.29"}, {"groupId": "OG001", "value": "48.11"}, {"groupId": "OG002", "value": "45.68"}, {"groupId": "OG003", "value": "43.65"}]}]}]}, {"type": "SECONDARY", "title": "Evaluation of the Percentage of Responders on Aliskiren 300 mg, 150 mg and 75 mg vs. Ramipril 5 mg, Define as msDBP < 90 mmHg or \u2265 10mmHg Decrease From Baseline in msDBP", "description": "To evaluate the percentage of responders on aliskiren 300 mg, 150 mg and 75 mg vs. ramipril 5 mg, defined as msDBP \\< 90 mmHg or \u2265 10mmHg decrease from baseline in msDBP.", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "OG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "OG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "OG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "318"}, {"groupId": "OG002", "value": "324"}, {"groupId": "OG003", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.89"}, {"groupId": "OG001", "value": "59.75"}, {"groupId": "OG002", "value": "59.57"}, {"groupId": "OG003", "value": "53.87"}]}]}]}, {"type": "PRIMARY", "title": "Non-inferiority of Aliskiren 300 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily"}, {"id": "OG001", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.63", "spread": "0.44"}, {"groupId": "OG001", "value": "-9.19", "spread": "0.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority margin of 2.25 mm Hg", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.44", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.63", "ciUpperLimit": "-1.25"}]}, {"type": "PRIMARY", "title": "Non-inferiority of Aliskiren 150 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 300 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily"}, {"id": "OG001", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "318"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.04", "spread": "0.44"}, {"groupId": "OG001", "value": "-9.19", "spread": "0.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority margin of 2.25 mm Hg", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.86", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.06", "ciUpperLimit": "0.34"}]}, {"type": "PRIMARY", "title": "Non-inferiority of Aliskiren 75 mg to Ramipril 5 mg in Change in Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "To evaluate the non-inferiority of aliskiren 75 mg to ramipril 5 mg in the change in Mean Sitting Diastolic Blood Pressure (msDBP) from baseline to 8 week endpoint", "populationDescription": "Intent-to-treat. Analyzed patients received at least one dose of study drug and had a post baseline measurement.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily"}, {"id": "OG001", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "324"}, {"groupId": "OG001", "value": "323"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.66", "spread": "0.44"}, {"groupId": "OG001", "value": "-9.19", "spread": "0.44"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "Non-inferiority margin of 2.25 mm Hg", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.48", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.67", "ciUpperLimit": "-0.28"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "8 weeks", "description": "One randomized patient in the Ramipril group never received blinded study medication. The subject is therefore not included in the \"at risk\" population.", "eventGroups": [{"id": "EG000", "title": "Aliskiren 300 mg", "description": "Aliskiren 300 mg once daily", "seriousNumAffected": 1, "seriousNumAtRisk": 331, "otherNumAffected": 4, "otherNumAtRisk": 331}, {"id": "EG001", "title": "Aliskiren 150 mg", "description": "Aliskiren 150 mg once daily", "seriousNumAffected": 2, "seriousNumAtRisk": 323, "otherNumAffected": 3, "otherNumAtRisk": 323}, {"id": "EG002", "title": "Aliskiren 75 mg", "description": "Aliskiren 75 mg once daily", "seriousNumAffected": 3, "seriousNumAtRisk": 332, "otherNumAffected": 2, "otherNumAtRisk": 332}, {"id": "EG003", "title": "Ramipril 5 mg", "description": "Ramipril 5 mg once daily", "seriousNumAffected": 1, "seriousNumAtRisk": 329, "otherNumAffected": 17, "otherNumAtRisk": 329}], "seriousEvents": [{"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}, {"term": "Medical device complication", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}, {"term": "Cerebral haemorrhage", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}, {"term": "Drug eruption", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 329}]}, {"term": "Varicose vein", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 329}]}], "otherEvents": [{"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 331}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 323}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 332}, {"groupId": "EG003", "numAffected": 17, "numAtRisk": 329}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017257", "term": "Ramipril"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}], "browseLeaves": [{"id": "M19553", "name": "Ramipril", "asFound": "Mandibular", "relevance": "HIGH"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}